Eli Lilly has entered into a $2 billion alliance with Repertoire in the field of autoimmune diseases. This step is part of biotechnological innovations in the field of pharmaceuticals. In addition, Eli Lilly announced the acquisition of biopharmaceutical company DICE Therapeutics, which focuses on the development of immunological drugs. The value of this purchase reaches 2.4 billion USD, which is approximately 52.3 billion CZK. These agreements strengthen Eli Lilly's position in the weight loss and immunotherapy market. Eli Lilly's market value recently surpassed $1 trillion thanks to the success of drugs like Mounjaro.